Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Theralase Technologies Inc. V.TLT

Alternate Symbol(s):  TLTFF

Theralase Technologies Inc. is a Canada-based clinical stage pharmaceutical company. The Company is engaged in the research and development of light, radiation, sound and/or drug-activated small molecule compounds, their associated drug formulations and the light systems that activate them, with a primary objective of efficacy and a secondary objective of safety in the destruction of various cancers, bacteria and viruses. It operates through two divisions: the Drug Division and the Device Division. The Drug Division is responsible for the research and development of light-activated small molecules primarily for the treatment of cancer with assistance from the Device Division to develop medical lasers to activate them. The Device Division is responsible for the Company’s medical laser business, which research, develops, manufactures and distributes cool laser therapy (CLT) systems to healthcare practitioners, predominantly for the healing of pain.


TSXV:TLT - Post by User

Bullboard Posts
Post by toade1313on Mar 17, 2015 11:11am
141 Views
Post# 23529452

SEC Form 20 F

SEC Form 20 F
SEC form 20 F mentioned at the end of the Korelin report. DEFINITION of 'SEC Form 20-F' A form issued by the Securities and Exchange Commission (SEC) that must be submitted by all "foreign private issuers" that have listed equity shares on exchanges in the United States. Form 20-F calls for the submission of an annual report within six months of the end of the company's fiscal year, or if the fiscal year-end date changes. The reporting and eligibility requirements for form 20-F are stated in the Securities Exchange Act of 1934. The information requirements are not as strict as for domestic U.S. companies; companies in which less than 50% of voting shares are held by U.S. investors may be eligible. INVESTOPEDIA EXPLAINS 'SEC Form 20-F' Once a company is deemed ineligible for foreign private issuer status, it must file the same forms as regular filers, such as 8-k, 10-Q, and 10-K reports, as well as reconciling accounting statements to GAAP standards. The goal of Form 20-F is to standardize the reporting requirements of foreign-based companies so that investors can evaluate these investments alongside domestic equities.
Bullboard Posts